Joint Pain After 50: Are Expensive Supplements and Injections Better Than Exercise, Weight Loss and Diclofenac?
Updated: Sep 24
A Narrative Review of Medical Nutrition Therapy, Exercise, Omega-3, Glucosamine, Chondroitin, Curcumin, NSAIDs and Joint Injections
Abstract
Joint pain becomes increasingly common after age 50, and consumers face a confusing marketplace of inexpensive generic medicines, dietary supplements, specialized exercise programs, and costly injections. Osteoarthritis (OA) is an important cause of this pain, but joint pain after 50 should not automatically be assumed to be OA.
This narrative review prioritizes systematic reviews, meta-analyses, randomized controlled trials, and major clinical guidelines published primarily during 2021–2026. It evaluates medical nutrition therapy (MNT), weight management, therapeutic exercise, omega-3 fatty acids, glucosamine, chondroitin, curcumin, topical and oral diclofenac, corticosteroid injections, hyaluronic acid (HA), and platelet-rich plasma (PRP). Where clinically meaningful, doses used in research or regulatory labeling are included.
The evidence does not support the assumption that more expensive treatment is necessarily more effective. Therapeutic exercise is a core OA treatment. For people with overweight or obesity, weight reduction can improve pain and physical function. When medication is required for knee OA, topical NSAIDs such as diclofenac have strong evidence and are considered cost-effective. NICE identifies topical NSAIDs as generally the most cost-effective medicines for OA.
Among supplements, omega-3 and curcumin have evidence of modest or potentially useful symptomatic effects, while glucosamine and chondroitin have inconsistent evidence. PRP is more interesting: recent randomized-trial meta-analysis suggests that it may provide longer-lasting improvement than corticosteroid injections in selected people with knee OA, although its cost and lack of standardization remain important limitations.
The practical conclusion is that expensive supplements and injections should generally not replace accurate diagnosis, appropriate exercise, nutrition therapy, weight management when indicated, and evidence-based pharmacologic treatment.
1. “Joint Pain After 50” Is a Symptom, Not a Diagnosis
Before asking which supplement or injection works best, the first question should be:
What is causing the pain?
Osteoarthritis typically causes activity-related pain, stiffness and progressive limitations in function. However, a person over 50 with joint pain may instead have rheumatoid or another inflammatory arthritis, gout or other crystal disease, bursitis, tendon disease, injury, infection, referred pain, or another medical condition.
This distinction matters because a treatment that produces modest pain relief in knee OA may be completely inappropriate for another disease.
A person with a suddenly hot, red and severely painful joint, fever, unexplained swelling, prolonged morning stiffness, multiple swollen joints, unexplained weight loss, substantial weakness, or rapidly worsening symptoms should receive medical assessment rather than simply starting a “joint supplement.”
The remainder of this review therefore focuses primarily on osteoarthritis, particularly knee OA, because that is where much of the comparative evidence exists.
2. Exercise: One of the Least Expensive Treatments Has Some of the Strongest Support
Therapeutic exercise is not merely general wellness advice for people with OA.
It is treatment.
NICE recommends individualized therapeutic exercise for all people with OA, including local muscle strengthening and general aerobic conditioning. Supervised therapeutic exercise should also be considered. Patients should be informed that discomfort can temporarily increase when exercise begins, but consistent long-term participation reduces pain and improves function and quality of life.
This is particularly important after 50 because inactivity can create a cycle:
Pain → less movement → muscle weakness → reduced joint support → poorer function → even less movement.
Appropriate exercise can interrupt that cycle.
Is there an exact therapeutic exercise “dose”?
Not in the same way that a medication has an exact dose.
The exercise program needs to reflect the affected joint, baseline strength, cardiovascular fitness, balance, pain severity, mobility and other medical conditions.
A practical rehabilitation program often incorporates progressive resistance exercise approximately 2–3 days per week, alongside regular aerobic activity such as walking, cycling, swimming or aquatic exercise according to tolerance. Balance and neuromuscular exercises can be added where appropriate.
However, this should not be interpreted as a universal prescription. Current guidelines emphasize individualized, progressive therapeutic exercise, rather than one mandatory number of minutes or repetitions for everyone.
The important therapeutic principles are consistency, appropriate progression and preservation or improvement of strength and function.
3. Medical Nutrition Therapy: Does an “Anti-Inflammatory Diet” Actually Work?
Nutrition is commonly promoted as a treatment for joint inflammation, but the evidence is more nuanced than advertising often suggests.
A 2025 systematic review and meta-analysis included nine randomized trials and 898 participants with OA. Dietary interventions collectively improved pain, physical function and body weight. Average weight reduction was approximately 3.18 kg.
Reduced-energy diets produced particularly favorable outcomes:
pain: SMD −0.85,
physical function: SMD −0.95,
body weight: approximately −3.13 kg.
Interestingly, Mediterranean-diet interventions by themselves did not significantly improve OA pain or physical function in the subgroup analysis.
This does not mean the Mediterranean diet lacks health benefits. It means we should avoid turning a generally healthy dietary pattern into an unsupported promise that it will directly eliminate OA pain.
What should MNT accomplish?
For a person with OA, MNT should support overall dietary quality, adequate protein and micronutrient intake, preservation of muscle mass, cardiometabolic health, and—when medically appropriate—sustainable weight reduction.
The goal is not simply to prescribe a list of supposedly “anti-inflammatory foods.”
4. Weight Loss: When It Is Appropriate, How Much Matters?
Weight reduction is relevant when OA coexists with overweight or obesity, particularly in weight-bearing joints.
NICE advises that weight loss can improve pain, function and quality of life in people with OA who are living with overweight or obesity. Importantly, there appears to be a dose-response relationship: any weight reduction may help, but approximately 10% body-weight reduction is likely to provide greater benefit than 5%.
For educational illustration:
Starting weight | 5% reduction | 10% reduction |
80 kg / 176 lb | 4 kg / 9 lb | 8 kg / 18 lb |
100 kg / 220 lb | 5 kg / 11 lb | 10 kg / 22 lb |
120 kg / 265 lb | 6 kg / 13 lb | 12 kg / 26 lb |
These are treatment reference targets, not requirements for a particular body size.
Intentional weight reduction may be inappropriate for someone with normal body weight, frailty, sarcopenia, inadequate food intake or unintentional weight loss. In those situations, preserving muscle and nutritional status may be more important.
5. Diclofenac: An Old and Inexpensive Treatment With Strong Evidence
Diclofenac is an NSAID—nonsteroidal anti-inflammatory drug.
NSAIDs decrease production of prostaglandins involved in pain and inflammation.
Diclofenac can be taken orally, but it can also be applied directly to a painful joint.
For knee OA, NICE recommends offering a topical NSAID. Oral NSAIDs can be considered when topical treatments are ineffective or unsuitable, but gastrointestinal, kidney, liver, cardiovascular, medication and comorbidity risks should first be considered.
NICE's economic evaluation is particularly relevant to the question behind this review: topical NSAIDs were found to be clinically effective for knee-OA pain and generally the most cost-effective medication strategy for OA.
Therapeutic dose: topical diclofenac 1% gel
For products with U.S. labeling equivalent to diclofenac sodium topical gel 1%, labeled OA dosing is generally:
Knee, ankle or foot:4 g applied to the affected joint four times daily.
Hand, wrist or elbow:2 g applied to the affected joint four times daily.
Product labeling limits also apply to the amount used per joint and total daily exposure, so patients should follow the instructions for their specific diclofenac formulation rather than assuming all topical diclofenac products are interchangeable.
This distinction is important because different diclofenac formulations and concentrations can have different dosing instructions.
6. What About Oral Diclofenac?
Oral diclofenac is effective, but its systemic exposure changes the risk-benefit calculation.
Depending on formulation, therapeutic OA regimens commonly fall around:
100–150 mg/day, divided according to the specific preparation.
Examples historically used in OA include 50 mg two or three times daily or 75 mg twice daily.
But this is exactly where a list of milligrams can become misleading.
For an older adult, the clinically appropriate question is not:
“What is the maximum dose?”
It is:
“What is the lowest effective exposure, for the shortest necessary duration, given this person's cardiovascular, gastrointestinal and kidney risks?”
NICE specifically recommends using pharmacologic treatments at the lowest effective dose for the shortest possible time. When an oral NSAID is used for OA, it recommends gastroprotection such as a proton-pump inhibitor.
People with chronic kidney disease, previous gastrointestinal ulcer or bleeding, cardiovascular disease, hypertension, anticoagulant treatment or multiple interacting medications require particular caution.
Therefore, topical diclofenac can be attractive for localized knee or hand OA because considerably less drug reaches the systemic circulation than with oral therapy.
7. Omega-3: Does Fish Oil Have a Therapeutic Effect?
Omega-3 fatty acids, particularly EPA and DHA, affect inflammatory signaling pathways.
A 2023 meta-analysis of nine randomized controlled trials involving 2,070 people with OA found omega-3 supplementation produced statistically significant improvements in pain:
SMD −0.29
and physical function:
SMD −0.21.
Overall adverse events were similar to placebo, and no severe treatment-related adverse events were reported in the included studies.
The magnitude of benefit, however, was relatively small.
Therapeutically relevant dose
Trials have used heterogeneous omega-3 preparations and doses, so there is no established universal therapeutic EPA+DHA dose for osteoarthritis.
Across the broader clinical literature, low-gram-per-day amounts of EPA+DHA are commonly encountered, but it would be inappropriate to present one number—such as 1, 2 or 4 g/day—as the proven OA dose.
For consumers, another distinction is critical:
1,000 mg of fish oil is not the same as 1,000 mg of EPA + DHA.
A capsule labeled “1,000 mg fish oil” may contain only a fraction of that amount as EPA and DHA.
Therefore, when evaluating products or research, the meaningful numbers are the actual EPA and DHA amounts per daily serving, not simply the weight of fish oil.
Practical conclusion
Omega-3 is a reasonable adjunct, with evidence for a small average improvement in symptoms.
It does not currently have evidence strong enough to replace therapeutic exercise or NSAIDs when those treatments are clinically appropriate.
8. Glucosamine: What Happens at the Dose Actually Used in Research?
Glucosamine is among the most heavily marketed “joint health” supplements.
The classic therapeutic research dose of glucosamine sulfate is:
1,500 mg/day
This is important because a product containing a much smaller amount should not automatically be assumed to reproduce results from trials using 1,500 mg.
But a studied dose is not the same thing as a proven effective dose.
A 2024 systematic review and meta-analysis examined 25 randomized trials: nine involving glucosamine sulfate, 13 involving chondroitin sulfate and three involving their combination.
Glucosamine sulfate was associated with a reduction in tibiofemoral joint-space narrowing, but the glucosamine/chondroitin combination did not significantly reduce pain or improve physical function.
NICE consequently takes a conservative position:
Do not offer glucosamine to manage osteoarthritis, because strong evidence of meaningful benefit is lacking.
Practical interpretation
Glucosamine sulfate 1,500 mg/day is a commonly studied therapeutic dose. It should not be interpreted as a guideline-endorsed OA treatment dose.
Paying more for glucosamine does not solve the underlying uncertainty regarding efficacy.
9. Chondroitin: More Promising Than Glucosamine?
The commonly studied chondroitin sulfate range is approximately:
800–1,200 mg/day
A frequently studied regimen is:
1,200 mg/day
either as one dose or, in older studies, 400 mg three times daily.
The 2024 systematic review found chondroitin sulfate significantly reduced pain and improved physical function compared with placebo. Both glucosamine and chondroitin showed generally favorable tolerability.
However, uncertainty remains.
One important problem is product equivalence.
A pharmaceutical-grade chondroitin preparation used in a randomized clinical trial should not automatically be assumed equivalent to every over-the-counter product labeled “chondroitin.”
Purity, source, manufacturing and actual ingredient content can differ.
Therefore:
800–1,200 mg/day represents the approximate research range, not a guarantee that every product at that dose will reproduce clinical-trial results.
10. Glucosamine + Chondroitin: More Ingredients Do Not Necessarily Mean More Benefit
A frequently studied combination is:
Glucosamine 1,500 mg/day + chondroitin 1,200 mg/day
Consumers might reasonably expect two “joint ingredients” to work better than one.
The evidence does not establish that.
In the 2024 meta-analysis, the combination did not significantly improve pain or physical function compared with placebo.
This provides a useful consumer-health lesson:
A supplement containing more active ingredients is not automatically a more effective treatment.
11. Curcumin and Turmeric: Promising, but Milligrams Can Be Misleading
Curcumin is one of the major bioactive compounds associated with turmeric.
A 2021 meta-analysis included 15 randomized trials and 1,621 participants. Compared with placebo, Curcuma longa extracts and curcumin preparations improved pain, function and stiffness. Some trials comparing them with NSAIDs produced similar outcomes with fewer adverse events.
This is promising—but should not be interpreted as proof that ordinary turmeric capsules are equivalent to diclofenac.
Therapeutically studied range
Clinical trials have commonly evaluated standardized curcumin/curcuminoid preparations in the approximate range of:
500–1,500 mg/day
with around 1,000 mg/day appearing frequently in clinical research.
However, curcumin has a major formulation problem.
Different products can have dramatically different bioavailability. Some contain specialized delivery systems or absorption enhancers.
Consequently:
1,000 mg of one standardized curcumin formulation may not produce the same exposure as 1,000 mg of another product.
And:
1,000 mg turmeric powder ≠ 1,000 mg purified or standardized curcuminoids.
Therefore, there is currently no defensible universal OTC “therapeutic turmeric dose” for OA.
12. Therapeutic Doses and Targets at a Glance
The following table belongs inside the review because dose is meaningful only when considered alongside efficacy, safety and evidence quality.
Intervention | Dose/target used in research or clinical practice | What the dose actually means |
Therapeutic exercise | Commonly strengthening ~2–3 days/week plus regular individualized aerobic activity | No single universal OA exercise dose; progression and adherence matter |
Weight management, when indicated | ≥5% body-weight reduction; around 10% may provide greater benefit | Guideline-supported target for people with overweight/obesity, not for everyone |
Topical diclofenac 1% gel | Lower extremity: 4 g 4×/day; upper extremity: 2 g 4×/day | Labeled therapeutic regimen; follow the specific product label |
Oral diclofenac | Common OA range approximately 100–150 mg/day, formulation-dependent | Effective but systemic risk is important; lowest effective dose/shortest duration |
Omega-3 EPA+DHA | Heterogeneous; low-gram/day ranges occur in trials | No established universal OA therapeutic dose |
Glucosamine sulfate | 1,500 mg/day | Commonly studied dose; efficacy remains inconsistent |
Chondroitin sulfate | 800–1,200 mg/day | Research range; product quality/formulation matters |
Glucosamine + chondroitin | 1,500 + 1,200 mg/day | Studied combination, but combination has not shown consistent superiority |
Curcumin/curcuminoids | Roughly 500–1,500 mg/day in many trials | Formulation and bioavailability make direct milligram comparisons unreliable |
Intra-articular corticosteroid | Preparation-dependent; triamcinolone acetonide 40 mg is a commonly studied knee dose | Clinician-administered; short-term relief rather than a universal dose |
Hyaluronic acid | Product-specific: single injection or multi-injection courses | No universal dose; NICE recommends against routine use |
PRP | No standardized therapeutic dose | Platelet dose, preparation, volume and number of injections vary |
Dose disclaimer
The doses above summarize amounts used in clinical trials, professional guidance or medication labeling and are presented for scientific and educational comparison. They are not individualized prescriptions. The appropriate treatment and dose can depend on the diagnosis, affected joint, age, kidney and cardiovascular health, gastrointestinal history, medications, bleeding risk and other clinical factors. Only an appropriately qualified healthcare professional should determine whether a medication, supplement or injection is appropriate and prescribe or recommend the individualized therapeutic dose.
13. Corticosteroid Injections: Effective, but Usually Short-Lived
Corticosteroid is injected directly into the affected joint to suppress inflammation and reduce symptoms.
A commonly studied knee-OA dose is:
Triamcinolone acetonide 40 mg intra-articularly
However, different corticosteroids and preparations use different doses, and this is a clinician-administered treatment—not a universal consumer dose.
The major limitation is duration.
NICE advises that intra-articular corticosteroid injections may be considered when other pharmacologic treatments are ineffective or unsuitable, or when short-term relief could help someone participate in therapeutic exercise.
Expected relief is generally:
approximately 2–10 weeks.
This makes corticosteroid particularly useful as a short-term tool, rather than a treatment expected to modify OA progression.
14. Hyaluronic Acid: Expensive Does Not Automatically Mean Better
Hyaluronic acid—sometimes called viscosupplementation—is injected into the joint.
There is no single therapeutic dose because products differ in molecular characteristics, concentration, injected volume and schedule. Depending on the preparation, treatment may involve one injection or a series of injections.
The more important issue is efficacy.
NICE recommends:
Do not offer intra-articular hyaluronan injections to manage osteoarthritis.
A 2024 meta-analysis of 35 randomized trials involving 3,348 patients compared corticosteroids with HA and PRP. HA did not produce better WOMAC outcomes than corticosteroids. Although long-term VAS pain favored HA statistically, the difference did not reach the minimal clinically important difference (MCID).
MCID is an important concept.
It asks:
“Is the difference large enough that the patient is likely to actually notice it?”
A result can be statistically significant without being meaningfully different in everyday life.
15. PRP: The Expensive Intervention With a More Interesting Evidence Signal
Platelet-rich plasma is prepared from a patient's own blood.
The blood is processed to concentrate platelets and associated biological factors, and the preparation is injected into the joint.
Unlike glucosamine or hyaluronic acid, PRP has accumulated a more interesting recent evidence signal.
The 2024 meta-analysis of 35 randomized trials found PRP produced greater WOMAC improvement than corticosteroid injections at short-, medium- and long-term follow-up. At medium- and long-term assessment, the differences exceeded the MCID, suggesting potentially clinically noticeable benefit.
That does not mean every PRP treatment works.
16. What Is the Therapeutic PRP Dose?
At present:
There is no established universal PRP therapeutic dose.
This is one of PRP's biggest scientific limitations.
PRP preparations differ in:
platelet concentration,
total platelet dose,
leukocyte content,
volume injected,
centrifugation technique,
activation method,
number of injections,
interval between injections.
Therefore, two clinics advertising “PRP for knee arthritis” may not actually be providing the same biological treatment.
Giving consumers one number in milliliters or one platelet concentration would create false precision.
The correct evidence-based statement is:
PRP is promising for selected knee-OA patients, but the field has not established a universally accepted preparation, platelet dose or injection schedule.
17. Supplements Versus Diclofenac Versus Injections
There are not enough direct head-to-head trials to calculate a scientifically valid single ranking for every treatment.
Nevertheless, the overall evidence allows useful comparison.
Treatment | Expected OA benefit | Evidence confidence | Cost tendency | Major limitation |
Therapeutic exercise | Meaningful pain/function benefit | High | $ | Requires continued participation |
Weight management when indicated | Meaningful/modest | Moderate–high | Variable | Appropriate only for selected patients |
Topical diclofenac/NSAID | Meaningful | High | $ | NSAID precautions still apply |
Oral NSAIDs | Meaningful | High | $ | GI, renal and cardiovascular risks |
Omega-3 | Small average benefit | Moderate/limited | $–$$ | No established OA dose |
Glucosamine | Inconsistent | Low–moderate | $–$$ | Major guideline recommends against use |
Chondroitin | Possible modest benefit | Low–moderate | $$ | Product/formulation variability |
Curcumin | Promising | Low–moderate | $–$$$ | Formulations are not interchangeable |
Corticosteroid injection | Short-term benefit | Moderate | $$ | Usually temporary |
Hyaluronic acid | Inconsistent/small | Moderate | $$$ | Poor value proposition in major guidance |
PRP | Promising, potentially longer lasting | Moderate/evolving | $$$$ | Expensive and poorly standardized |
The table highlights the central finding of this review:
Cost and clinical effectiveness are not the same thing.
18. What Gives the Best Value?
For uncomplicated knee OA, therapeutic exercise is difficult to beat as a foundational treatment because it addresses function, strength and mobility as well as symptoms.
For someone living with overweight or obesity, MNT and sustainable weight reduction add another evidence-supported strategy. A 5% reduction can be meaningful, while approximately 10% may provide greater benefit.
When medication is needed, topical NSAIDs such as diclofenac have a particularly favorable evidence-to-cost relationship for knee OA. NICE specifically found topical NSAIDs generally the most cost-effective medication option.
Omega-3 may provide a small additional benefit and has reasonable evidence as an adjunct.
Curcumin is promising, but consumers should understand that formulation matters enormously.
Glucosamine is difficult to recommend as a high-value routine purchase because major guidelines find its clinical benefit insufficiently convincing.
Chondroitin has a somewhat more favorable recent research signal, but product variability and inconsistency prevent it from replacing established therapy.
Routine HA injections are difficult to justify based on current evidence and guideline recommendations.
PRP is different. It is expensive, but recent evidence suggests that some patients with knee OA may experience longer-lasting benefit than with corticosteroid injection. It is therefore reasonable to discuss after appropriate conservative management, rather than dismissing it simply because it is expensive.
19. The Best Treatment May Be a Combination, Not a Winner
The question “exercise or diclofenac?” creates a false competition.
An individualized treatment strategy might use topical diclofenac to reduce knee pain sufficiently for someone to begin strengthening exercises.
Exercise may improve function and muscle capacity.
MNT may facilitate weight reduction when appropriate.
A supplement may provide a small additional benefit.
An injection might later be considered if substantial symptoms persist despite conservative treatment.
This is consistent with NICE's recommendation that pharmacologic treatments be used alongside non-pharmacologic treatments and to support therapeutic exercise, rather than replacing them.
The goal is not to find the strongest isolated treatment.
The goal is to construct the safest combination that allows the individual to move better, function better and experience less pain.
20. “Inflammation” After 50 Should Not Automatically Be Treated With Supplements
The word “inflammation” is heavily used in supplement marketing.
But unexplained inflammation is not a diagnosis.
Persistent swelling, warmth, prolonged morning stiffness, sudden severe joint pain, multiple affected joints, fever or systemic symptoms can point toward inflammatory arthritis, gout, infection or another disorder.
Rheumatoid arthritis is especially important.
NSAIDs may reduce rheumatoid-arthritis pain, but they do not adequately control the underlying autoimmune disease. Omega-3 or curcumin may also affect symptoms, but neither should substitute for appropriate disease-modifying therapy.
A person with suspected inflammatory arthritis should therefore be medically evaluated rather than spending months experimenting with supplements.
21. Joint Health Is Not the Same as Bone Health
“Bone and joint health” are frequently marketed together, but osteoarthritis and osteoporosis are different diseases.
OA primarily involves the joint.
Osteoporosis involves reduced bone strength and increased fracture risk.
Osteoporosis can exist without chronic joint pain.
Likewise, knee pain does not prove that someone has weak bones.
Calcium and vitamin D therefore should not automatically be prescribed as treatments for OA pain simply because the patient is over 50.
Bone-health assessment should be based on osteoporosis and fracture risk rather than joint pain alone.
22. Safety Becomes More Important After 50
A treatment with modest benefit can become a poor choice if its risks are substantial for a particular person.
This is especially relevant with oral NSAIDs.
People with chronic kidney disease, previous stomach ulcers or GI bleeding, cardiovascular disease, hypertension, anticoagulant treatment or complex medication regimens require careful evaluation before systemic NSAID therapy. NICE explicitly instructs clinicians to consider gastrointestinal, renal, hepatic and cardiovascular toxicity when considering oral NSAIDs.
Supplements deserve similar respect.
“Natural” does not mean pharmacologically inactive.
Omega-3, concentrated curcumin products and other supplements can interact with medications or be inappropriate in particular clinical circumstances.
And with supplements, another question should always be:
Was the actual commercial product tested—or only an ingredient that sounds similar?
23. A Rational Stepwise Strategy After Age 50
For a person with suspected OA, a sensible evidence-based pathway begins with establishing the diagnosis and identifying red flags.
Once OA is established, therapeutic exercise and education form the foundation. MNT and sustainable weight reduction should be incorporated when overweight or obesity is clinically relevant.
If knee pain interferes with function or exercise, topical diclofenac or another topical NSAID is among the best-supported medication options, assuming it is clinically appropriate.
Supplements can then be discussed as adjuncts. Omega-3 has evidence for a small average benefit. Curcumin is promising but formulation-dependent. Chondroitin may benefit some people. Routine glucosamine has a weaker rationale.
If symptoms remain substantial, reconsidering the diagnosis is important before simply adding more products.
Corticosteroid injection can provide temporary relief. Routine HA injection has weak justification under current major guidance. PRP may be worth discussing in selected persistent knee-OA cases, with an explicit conversation about cost, uncertainty and lack of standardization.
24. Final Conclusion: Does Expensive Mean Better?
No.
The evidence does not show a reliable relationship between price and effectiveness for osteoarthritis treatment.
Some of the strongest interventions are relatively inexpensive:
therapeutic exercise, appropriate weight management and topical NSAIDs such as diclofenac.
Among supplements, omega-3 has evidence for a small average improvement in OA pain and function. Chondroitin has shown benefits in some analyses but remains less dependable than established first-line treatments. Glucosamine has inconsistent evidence despite its enormous commercial popularity. Curcumin is promising, but highly variable formulations make ordinary supplement-to-supplement comparisons difficult.
The therapeutic doses also tell an important story:
Glucosamine sulfate 1,500 mg/day is a studied dose—but a studied dose does not make it a proven treatment.
Chondroitin sulfate 800–1,200 mg/day represents a common research range—but OTC product quality matters.
Curcumin approximately 500–1,500 mg/day appears frequently in trials—but different formulations may produce dramatically different exposure.
Omega-3 has no established universal OA therapeutic EPA+DHA dose, despite evidence of a small benefit.
Topical diclofenac has defined medication-label dosing and strong guideline support.
And PRP has promising clinical evidence but no universally standardized therapeutic dose at all.
This is why consumers should not judge treatments by price, milligrams on the bottle, number of ingredients, or the words “advanced” and “premium.”
The better question is:
Which treatment provides a clinically meaningful improvement in pain, mobility and quality of life, with acceptable risk and reasonable cost for this particular person?
For many adults over 50 with osteoarthritis, the evidence suggests beginning with an accurate diagnosis, progressive therapeutic exercise, appropriate nutrition and weight management, and selective evidence-based pain treatment—not automatically with the most expensive supplement or injection.
Selected References
Asadi S, et al. The effectiveness of dietary intervention in osteoarthritis management: a systematic review and meta-analysis of randomized clinical trials. European Journal of Clinical Nutrition. 2025;79:959–971. Nine RCTs and 898 participants. PMID 40295866.
Deng W, et al. Effect of omega-3 polyunsaturated fatty acids supplementation for patients with osteoarthritis: a meta-analysis. Journal of Orthopaedic Surgery and Research. 2023;18:381. Nine RCTs and 2,070 participants. PMID 37226250.
Rabade A, et al. Evaluation of efficacy and safety of glucosamine sulfate, chondroitin sulfate, and their combination regimen in the management of knee osteoarthritis: a systematic review and meta-analysis. Inflammopharmacology. 2024;32:1759–1775. Twenty-five RCTs. PMID 38581640.
Bensa A, et al. Corticosteroid injections for knee osteoarthritis offer clinical benefits similar to hyaluronic acid and lower than platelet-rich plasma: a systematic review and meta-analysis. EFORT Open Reviews. 2024;9:883–895. Thirty-five RCTs and 3,348 patients. PMID 39222336.
Zeng L, et al. The efficacy and safety of Curcuma longa extract and curcumin supplements on osteoarthritis: a systematic review and meta-analysis. Bioscience Reports. 2021;41(6):BSR20210817. Fifteen RCTs and 1,621 participants. PMID 34017975.
National Institute for Health and Care Excellence. Osteoarthritis in over 16s: diagnosis and management (NG226). Recommendations cover therapeutic exercise, weight management, topical and oral NSAIDs, glucosamine and intra-articular therapy.
Author and Disclosure
Disclosure: The author reports no financial relationship with manufacturers of diclofenac, NSAIDs, omega-3, glucosamine, chondroitin, curcumin, hyaluronic acid, PRP systems, or other products discussed in this review. No manufacturer or supplement company participated in the preparation of this article.
Editorial and evidence disclosure: This is a narrative review intended to translate research and professional guidance into understandable health information. It is not a systematic review or clinical practice guideline. Priority was given to systematic reviews, meta-analyses, randomized controlled trials and major professional guidelines, particularly evidence published during approximately 2021–2026. Older evidence may be used when necessary to describe established therapeutic doses or foundational evidence. Inclusion of a medication, supplement, dose or procedure does not constitute endorsement.
Medical and dosage disclaimer: All medication doses, supplement ranges, exercise targets, weight-management targets and injection doses described in this review are included for educational discussion of the scientific literature. They are not personal prescriptions. There is no single appropriate dose for every adult over 50. Only an appropriately qualified healthcare professional should determine the diagnosis and prescribe or recommend the appropriate dose and treatment after considering medical history, kidney and liver function, cardiovascular and gastrointestinal risk, allergies, medications, nutritional status and other individual factors. New, severe, persistent, swollen, hot or otherwise unexplained joint pain should receive appropriate medical evaluation.
Comments